<DOC>
	<DOCNO>NCT01434693</DOCNO>
	<brief_summary>This sequential dose-escalation ( 3 dose level TSO , ie , 500 , 2500 , 7500 TSO ) , randomize ( within 3 period , ratio 3:1 TSO placebo ) , double-blind , placebo-controlled study evaluate safety single dose oral CNDO-201 Trichuris suis ovum suspension , compare placebo , patient Crohn 's Disease .</brief_summary>
	<brief_title>Safety Tolerability Single Doses Oral CNDO 201 Trichuris Suis Ova Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Males female , 18 55 year old . 2 . Patient confirm diagnosis Crohn 's Disease establish criterion minimum disease duration 3 month . 3 . If patient use concomitant medication , dose/regimen stable remains stable two week close observation follow TSO administration . Concomitant medication may include : 1 ) Oral sulfasalazine , mesalazine ( 5ASA ) , mesalazine derivative , receive &gt; 6 week receive dose least 4 week ; 2 ) Oral prednisone 15 mg/day , receive &gt; 4 week receive dose least 2 week ; 3 ) Azathioprine 6mercaptopurine receive &gt; 3 month receive dose least 8 week . 4 . Hemoglobin ≥ 12 g/dL screening . 5 . Normal white blood cell count normal lymphocyte count screening . 6 . Platelet count &gt; low limit normal screening . 7 . For female childbearing potential , negative serum pregnancy test screening period , breastfeed study duration , willingness use accept form reliable birth control study duration [ include bilateral tubal ligation , use oral contraceptive , double barrier method ( diaphragm spermicidal gel condom contraceptive foam ) , DepoProvera® , hormonal implant , partner vasectomy , total abstinence ] . Pregnancy test require ( indicate `` N/A '' ) males female childbearing potential ( postmenopausal last menstrual period &gt; 1 year ago total hysterectomy ) . 8 . Patient must ability provide informed consent . 1 . Patient ulcerative colitis , indeterminate colitis , ulcerative proctitis . 2 . Bowel surgery past 6 month . 3 . Resection 50 cm ileum . 4 . Ileostomy colostomy . 5 . Septic complication . 6 . Patient hospitalize exhibit sign toxicity ( sepsis ) , significant multiple stricture , impend obstruction ( evidence abdominal distension , severe abdominal tenderness , fever , nausea , vomit , tachycardia ) anticipate need blood transfusion gastrointestinal bleeding surgical intervention may imminent . 7 . Patient gastrointestinal abscess , perforation , active drain fistula fistula consider clinically significant perianal lesion . 8 . Patient history colorectal cancer colorectal dysplasia . 9 . Parenteral tube feeding . 10 . Patient evidence infectious colitis , e.g. , Clostridium difficile , Amoebiasis , Giardia lamblia stool positive enteric pathogen , ova parasite Screening . 11 . Female patient pregnant breastfeeding wish become pregnant study participation unwilling use birth control . 12 . Patient serum creatinine ≥ 2.0 mg/dL ; blood urea nitrogen &gt; 40 mg/dL ; alkaline phosphatase &gt; 250 U/L ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 100 U/L ; total bilirubin &gt; 1.5 mg/dL . 13 . Patient white blood count &lt; 5,000 &gt; 15,000/mm3 ; platelet count &lt; 150,000 per μl ; iron vitamin B12 deficiency . Correction lab exclusion allow provided medical condition deem put patient risk stability result sustain minimum 30 day . 14 . Patient active hepatitis B virus , hepatitis C virus , liver cirrhosis portal hypertension , cytomegalovirus , Epstein Barr Virus herpes simplex virus know human immunodeficiency virus ( HIV ) positive . 15 . Patient primary sclerosing cholangitis . 16 . Patient active malignancy treatment anticancer drug past 5 year . 17 . Patient receive cyclosporine , antiTNF immunomodulatory agent azathioprine/6mercaptopurine 12 week prior Screening . 18 . Patient receive methotrexate 4 week prior Screening . 19 . Patient receive metronidazole 2 week prior Screening . 20 . Patient receive nonsteroidal antiinflammatory drug ( NSAIDS ) within 2 week Baseline visit 3 consecutive day , except acetylsalicylic acid ≤ 350 mg/d allow . 21 . Patient receive antibiotic , antifungal antiparasitic medication last 2 week prior Screening and/or would potentially require study treatment period . 22 . Patient history drug alcohol abuse within 6 month prior Screening . 23 . Patient evidence poor compliance medical advice instruction include diet medication . 24 . Patient unable unwilling swallow study medication suspension . 25 . Patient significant medical condition put patient risk study participation and/or reason consider Investigator unsuitable candidate receive CNDO201 TSO potentially put risk study procedure . 26 . Patients participate another clinical trial within 30 day Screening trial and/or experimental treatment population .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>T. suis ovum</keyword>
	<keyword>Crohn 's disease</keyword>
</DOC>